Disseminated intravascular coagulation following administration of sunitinib

  • Authors:
    • Anaëlle Olivo
    • Nicolas Noël
    • Benjamin Besse
    • Anne‑Marie Taburet
    • Olivier Lambotte
  • View Affiliations

  • Published online on: May 11, 2016     https://doi.org/10.3892/mco.2016.896
  • Pages: 121-123
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Sunitinib is an increasingly used, orally administered targeted therapy, approved by the European Medicines Agency for the treatment of various types of cancer, including gastrointestinal stromal tumor unresectable or metastatic disease, following disease progression or intolerance to imatinib, and advanced or metastatic renal cell carcinoma, progressive well-differentiated pancreatic neuroendocrine tumors in patients with unresectable, locally advanced or metastatic disease. Sunitinib inhibits several tyrosine kinases, including the vascular endothelial growth factor receptor and the platelet-derived growth factor receptor. Tyrosine kinases inhibitor therapies are generally well‑tolerated; nonetheless, they are not void of side effects. The majority of patients reported are grade 1 or 2, and include common and unspecific adverse events, including fatigue, gastrointestinal disorders, skin discoloration, altered taste, cough and dyspnea. Grade 3 or 4 adverse events, including bleeding and hemorrhage, are less frequent. The present study presented the first case of disseminated intravascular coagulation associated with the administration of sunitinib, shortly following the increase of sunitinib dosage.
View Figures
View References

Related Articles

Journal Cover

July 2016
Volume 5 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Olivo, A., Noël, N., Besse, B., Taburet, A., & Lambotte, O. (2016). Disseminated intravascular coagulation following administration of sunitinib. Molecular and Clinical Oncology, 5, 121-123. https://doi.org/10.3892/mco.2016.896
MLA
Olivo, A., Noël, N., Besse, B., Taburet, A., Lambotte, O."Disseminated intravascular coagulation following administration of sunitinib". Molecular and Clinical Oncology 5.1 (2016): 121-123.
Chicago
Olivo, A., Noël, N., Besse, B., Taburet, A., Lambotte, O."Disseminated intravascular coagulation following administration of sunitinib". Molecular and Clinical Oncology 5, no. 1 (2016): 121-123. https://doi.org/10.3892/mco.2016.896